Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM). In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vilda...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundhun, Pravesh Kumar, Janoo, Girish, Teeluck, Abhishek Rishikesh, Huang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651605/
https://www.ncbi.nlm.nih.gov/pubmed/29058622
http://dx.doi.org/10.1186/s40360-017-0175-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651605/
https://www.ncbi.nlm.nih.gov/pubmed/29058622
http://dx.doi.org/10.1186/s40360-017-0175-0

Ejemplares similares